Scholarlink

Background <p>Renin–angiotensin system (RAS) blockers constitute a&#xa0;cornerstone in the management of patients with cardiovascular disease. However, the relationship between the administration time of these drugs during the day and cardiovascular events is not yet fully elucidated. We aimed to examine the relationship between the administration time of RAS blockers during the day and long-term cardiovascular outcomes in patients with ST-segment elevation myocardial infarction (STEMI).</p> Methods <p>A&#xa0;total of 701 patients who were admitted to our hospital between 2018 and 2020 with STEMI and underwent primary percutaneous coronary intervention (PCI) were included in this single-center, retrospective, observational study. Primary endpoints were acute heart failure (AHF), nonfatal myocardial infarction, major adverse cardiovascular events (MACE), and long-term mortality. Patients were divided into two group according to the administration of RAS blockers in the morning (06:00–10:00) or evening (20:00–00:00).</p> Results <p>The mean age of the patients was 57.5 ± 11.9&#xa0;years and 75.9% were male. After discharge, 485 patients were taking RAS blockers in the morning and 216 patients were taking them in the evening. There was a&#xa0;significantly higher rate of AHF, nonfatal myocardial infarction, MACE, and death in the group taking RAS blockers in the morning compared to the group taking them in the evening (<i>p</i> &lt; 0.01, <i>p</i> = 0.02, <i>p</i> &lt; 0.01, <i>p</i> &lt; 0.01, respectively).</p> Conclusion <p>Routine administration of RAS blockers in the evening rather than in the morning led to a&#xa0;remarkable decrease in the occurrence of AHF, nonfatal myocardial infarction, MACE, and mortality.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Timing of RAS blocker administration and long-term cardiovascular outcomes in STEMI patients

  • 期刊论文

  • 发表日期：

    2025年6月16日

查看全文
  • Tuğba Çetin,
  • Mehmet Baran Karataş,
  • Semih Eren,
  • Şeyda Dereli,
  • Gündüz Durmuş

摘要

Background

Renin–angiotensin system (RAS) blockers constitute a cornerstone in the management of patients with cardiovascular disease. However, the relationship between the administration time of these drugs during the day and cardiovascular events is not yet fully elucidated. We aimed to examine the relationship between the administration time of RAS blockers during the day and long-term cardiovascular outcomes in patients with ST-segment elevation myocardial infarction (STEMI).

Methods

A total of 701 patients who were admitted to our hospital between 2018 and 2020 with STEMI and underwent primary percutaneous coronary intervention (PCI) were included in this single-center, retrospective, observational study. Primary endpoints were acute heart failure (AHF), nonfatal myocardial infarction, major adverse cardiovascular events (MACE), and long-term mortality. Patients were divided into two group according to the administration of RAS blockers in the morning (06:00–10:00) or evening (20:00–00:00).

Results

The mean age of the patients was 57.5 ± 11.9 years and 75.9% were male. After discharge, 485 patients were taking RAS blockers in the morning and 216 patients were taking them in the evening. There was a significantly higher rate of AHF, nonfatal myocardial infarction, MACE, and death in the group taking RAS blockers in the morning compared to the group taking them in the evening (p < 0.01, p = 0.02, p < 0.01, p < 0.01, respectively).

Conclusion

Routine administration of RAS blockers in the evening rather than in the morning led to a remarkable decrease in the occurrence of AHF, nonfatal myocardial infarction, MACE, and mortality.